Skip to content
thestock.space

As of 6 Nov 2026, Alkem Laboratories trades at 29.4× trailing earnings, above the industry P/E of 28.7×, and the shares are 11% below their 52-week high. It earns ROCE of 19% and ROE of 18%, and sales and net profit grew 8.3% and 33% a year over 3 years. Its dividend yield is 0.4%, and debt is 0.14× equity. It is a mid-cap company with a market cap of ₹63,334 Cr, ranked 12th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 8.4% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹5,186.50
Day high
₹5,297.00
Day low
₹5,141.00
Prev. close
₹5,190.00
Volume
65.9K

Health check

4 fair · 2 to check
  • ReturnsBehind

    −8.4% over a year, better than 0 of 7 peers.

  • Price tagIn line

    P/E 29.4 vs industry 28.7.

  • GrowthSteady

    Sales +8.3%, profit +32.7% a year over 3 years.

  • ProfitabilityAverage

    ROCE 18.6% vs peer median 17.9%.

  • Balance sheetFair

    Debt 0.14× equity, interest covered 25.8×, Piotroski 4 of 9.

  • Red flags2 to check

    Quarterly profit down 21.7% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Mid cap

₹63,334 Cr, #12 of 154 in its industry by size.

Defensive

Beta 0.29 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹15,081 Cr · profit ₹2,158 Cr
Market cap
₹63,334 Cr
Mid cap
P/E
29.4
Industry 28.7
Price to book
4.58
Peers 4.99
Dividend yield
0.38%
ROE
17.8%
Peers 14.7%
ROCE
18.6%
Peers 17.9%
Debt to equity
0.14
Debt ₹2,047 Cr
EPS (TTM)
₹180.44
Face value ₹2
OPM (TTM)
20.1%
Net margin 14.3%
Sales growth
+10.9%
Latest quarter vs a year ago
Profit growth
−21.7%
Latest quarter vs a year ago
Price to sales
4.20
EV/EBITDA 21.1

Strengths and risks

Strengths

  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Quarterly profit down 21.7% on a year ago.
  • Promoter stake down from 53.0% to 49.7%.

Derived automatically from reported figures. Not a recommendation.

About Alkem Laboratories

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers biosimilars, active pharmaceutical ingredients, branded and trade generics, complex generics, and consumer wellness products in therapeutic areas comprising anti – infective, anti-osteoporosis, cardiology, neurology,…

Headquarters
Mumbai
Employees
19,346
Sector
Healthcare
ISIN
INE540L01014
Website
alkemlabs.com

Price range

52 weeks

₹4,811.00₹5,933.50

Today

₹5,141.00₹5,297.00
Avg volume (3M)
1.4 L
1-year return
minus 8.4%
From 52-week high
minus 10.7%

Analyst consensus

20 analysts
No consensusMean target ₹6,002.55 plus 13.3%

Target range, with today’s price

Low ₹4,590.00High ₹6,850.00

Next results expected around 12 Nov 2026

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
ALKEMAlkem Laboratories5,297.00plus 2.06%63,33429.44.5818.6%17.8%20.1%8.3%32.7%0.38%minus 8.4%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
3,3714,0013,7373,6033,740
2,6323,0802,9093,0862,974
739921828517766
21.9%23.0%22.2%14.4%20.5%
136104143200153
29.83542.153.946.6
87.793.695106100
12.9–−52.8−135–
771896781423772
13.3%13.0%16.3%40.5%32.4%
664765636236520
55.5663.9953.1919.7743.49

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+8.3%
Profit CAGR 3Y
+32.7%
EPS CAGR 3Y
+32.7%
ROE
17.8%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
11,44012,43912,80514,532
–+8.7%+2.9%+13.5%
9,79610,15510,26311,501
1,6452,2842,5413,031
14.4%18.4%19.8%20.9%
151243386460
93.895.787.2116
310299357382
−86.7−11043.8−123
1,3052,0232,5272,871
22.8%10.5%12.3%18.0%
9841,7962,1652,302
–+82.5%+20.6%+6.3%
82.31150.19181.11192.51

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
23.923.923.923.9
9,02110,28811,96113,796
1,3971,4181,3812,047
3,3153,8444,3255,006
13,75715,57517,69120,873
2,5142,5962,9323,346
310187546255
5654051,0361,521
1,1434,2703,7784,065
9,2258,1179,39911,686
13,75715,57517,69120,873

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
1,6831,9481,9131,963
113−1,009−1,299−1,667
−1,761−1,145−811−503
34.5−205−197−208
−233−259−676−617
1,4501,6891,2371,346
−530−540−505−614

Shareholding pattern

Source: NSE filings
49.7%
promoters
  • Promoters49.70%
  • Public50.30%
  • As of 30 Jun 2026
QuarterSplitPromotersPublicPromoter change
30 Jun 202649.70%50.30%minus 1.50
31 Mar 202651.20%48.80%0.00
31 Dec 202551.20%48.80%0.00
30 Sep 202551.20%48.80%minus 1.84
30 Jun 202553.04%46.96%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you